Inhibition of hypoxia-induced proliferation of pulmonary arterial smooth muscle cells by a mTOR siRNA-loaded cyclodextrin nanovector

Biomaterials

Volumn 35, Issue 14, 2014, Pages 4401-4416

  Liu, Xueping ^a   Wang, Guansong ^a   You, Zaichun ^a   Qian, Pin ^a   Chen, Huaping ^a   Dou, Yin ^a   Wei, Zhenghua ^a   Chen, Yan ^a   Mao, Chengde ^b   Zhang, Jianxiang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Cyclodextrin; Gene delivery; Nanovector; PH sensitive; SiRNA therapy; Smooth muscle cell

Indexed keywords

GENE DELIVERY; NANOVECTOR; PH SENSITIVE; SIRNA THERAPIES; SMOOTH MUSCLE CELLS;

ANTIBIOTICS; CELL DEATH; COPOLYMERS; CYCLODEXTRINS; GENE TRANSFER; HYBRID MATERIALS; LIPOSOMES; LOADING; PROTEINS; RNA;

GENE THERAPY;

CYCLODEXTRIN; LIPOFECTAMINE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; NANOCARRIER; POLYETHYLENEIMINE; POLYGLACTIN; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA; THYMIDINE;

ANIMAL CELL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CELL HYPOXIA; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENDOSOME; FLOW CYTOMETRY; FLUORESCENCE; GENE THERAPY; GROWTH INHIBITION; HYDROLYSIS; IN VITRO STUDY; LYSOSOME; MOLECULAR WEIGHT; MTT ASSAY; MUSCLE CELL; NANOMEDICINE; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERIAL SMOOTH MUSCLE CELL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SMOOTH MUSCLE FIBER;

MAMMALIA;

CYCLODEXTRIN; GENE DELIVERY; NANOVECTOR; PH-SENSITIVE; SIRNA THERAPY; SMOOTH MUSCLE CELL;

ANIMALS; APOPTOSIS; CELL HYPOXIA; CELL PROLIFERATION; CYCLODEXTRINS; ENDOCYTOSIS; GENETIC VECTORS; MALE; MYOCYTES, SMOOTH MUSCLE; NANOMEDICINE; NANOPARTICLES; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSFECTION;

EID: 84896705733     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.02.009     Document Type: Article

References (59)

1. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004, 351:1425-1436.
2. Ryan J.J., Marsboom G., Archer S.L. Rodent models of group 1 pulmonary hypertension 2013, Springer, Heidelberg. 2013/10/05 ed.
3. Pullamsetti S.S., Berghausen E.M., Dabral S., Tretyn A., Butrous E., Savai R., et al. Role of Src tyrosine kinases in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol 2012, 32:1354-1365.
4. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
5. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
6. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011, 12:21-35.
7. Johnson S.C., Rabinovitch P.S., Kaeberlein M. cancer, cardiovascular disease, autoimmunity, and metabolic disorders. Nature 2013, 493:338-345.
8. Houssaini A., Abid S., Mouraret N., Wan F., Rideau D., Saker M., et al. Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension. Am J Respir Cell Mol Biol 2013, 48:568-577.
9. Humar R., Kiefer F.N., Berns H., Resink T.J., Battegay E.J. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 2002, 16:771-780.
10. van Rooij E., Olson E.N. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 2012, 11:860-872.
11. Leuschner F., Dutta P., Gorbatov R., Novobrantseva T.I., Donahoe J.S., Courties G., et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 2011, 29:1005-1011.
12. Vaishnaw A.K., Gollob J., Gamba-Vitalo C., Hutabarat R., Sah D., Meyers R., et al. A status report on RNAi therapeutics. Silence 2010, 1:1-14.
13. Moss S.C., Lightell D.J., Marx S.O., Marks A.R., Woods T.C. Rapamycin regulates endothelial cell migration through regulation of the cyclin-dependent kinase inhibitor p27Kip1. J Biol Chem 2010, 285:11991-11997.
14. Ma K.L., Liu J., Wang C.X., Ni J., Zhang Y., Wu Y., et al. Activation of mTOR modulates SREBP-2 to induce foam cell formation through increased retinoblastoma protein phosphorylation. Cardiovasc Res 2013, 100:450-460.
15. Gilleron J., Querbes W., Zeigerer A., Borodovsky A., Marsico G., Schubert U., et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol 2013, 31:638-646.
16. Thomas C.E., Ehrhardt A., Kay M.A. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003, 4:346-358.
17. Zhang J.X., Li X.H., Lou L.P., Li X.D., Jia Y., Jin Z., et al. Non-viral gene therapy. Intracellular delivery: fundamentals and applications 2011, 599-699. Springer Science+Business Media. 1st ed. A. Prokop (Ed.).
18. Kesharwani P., Gajbhiye V., Jain N.K. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 2012, 33:7138-7150.
19. Mintzer M.A., Simanek E.E. Nonviral vectors for gene delivery. Chem Rev 2009, 109:259-302.
20. Kanasty R., Dorkin J.R., Vegas A., Anderson D. Delivery materials for siRNA therapeutics. Nat Mater 2013, 12:967-977.
21. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009, 8:129-138.
22. Chen H.P., Liu X.P., Dou Y., He B.F., Liu L., Wei Z.H., et al. A pH-responsive cyclodextrin-based hybrid nanosystem as a nonviral vector for gene delivery. Biomaterials 2013, 34:4159-4172.
23. Zhang J.X., Jia Y., Li X.D., Hu Y.Q., Li X.H. Facile engineering of biocompatible materials with pH-modulated degradability. Adv Mater 2011, 23:3035-3040.
24. Wang Y., Zhou J.Z., Tang Y., Wei Y.L., Gong H., Li X.H., et al. Nanocomplexation-assisted solubilization of pDNA in organic solvents for improved microencapsulation. J Colloid Interface Sci 2013, 394:573-581.
25. Zhang J.X., Chen D., Wang S.J., Zhu K.J. Optimizing double emulsion process to decrease the burst release of protein from biodegradable polymer microspheres. J Microencapsul 2005, 22:413-422.
26. Liu T., Li Y., Lin K., Yin H., He B., Zheng M., et al. Regulation of S100A4 expression via the JAK2-STAT3 pathway in rhomboid-phenotype pulmonary arterial smooth muscle cells exposure to hypoxia. Int J Biochem Cell Biol 2012, 44:1337-1345.
27. Yin H., Li Q., Qian G., Wang Y., Li Y., Wu G., et al. Rab1 GTPase regulates phenotypic modulation of pulmonary artery smooth muscle cells by mediating the transport of angiotensin II type 1 receptor under hypoxia. Int J Biochem Cell Biol 2011, 43:401-408.
28. Wang G., Zhou D., Wang C., Gao Y., Zhou Q., Qian G., et al. Hypoxic preconditioning suppresses group III secreted phospholipase A2-induced apoptosis via JAK2-STAT3 activation in cortical neurons. J Neurochem 2010, 114:1039-1048.
29. Panyam J., Zhou W.Z., Prabha S., Sahoo S.K., Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J 2002, 16:1217-1226.
30. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003, 55:329-347.
31. Davis M.E., Brewster M.E. Cyclodextrin-based pharmaceutics: past, present, and future. Nat Rev Drug Discov 2004, 3:1023-1035.
32. Zhang J.X., Ma P.X. Cyclodextrin-based supramolecular systems for drug delivery: recent progress and future perspective. Adv Drug Deliv Rev 2013, 65:1215-1233.
33. Zhang J.X., Ma P.X. Host-guest interactions mediated nano-assemblies using cyclodextrin-containing hydrophilic polymers and their biomedical applications. Nano Today 2010, 5:337-350.
34. He H., Chen S., Zhou J., Dou Y., Song L., Che L., et al. Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel. Biomaterials 2013, 34:5344-5358.
35. Khalil I.A., Kogure K., Akita H., Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev 2003, 58:32-45.
36. Sahay G., Alakhova D.Y., Kabanov A.V. Endocytosis of nanomedicines. J Control Release 2010, 145:182-195.
37. Bareford L.M., Swaan P.W. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 2007, 59:748-758.
38. Suh H., Jeong B., Liu F., Kim S.W. Cellular uptake study of biodegradable nanoparticles in vascular smooth muscle cells. Pharm Res 1998, 15:1495-1498.
39. Gu Z., Rolfe B.E., Thomas A.C., Campbell J.H., Lu G.Q., Xu Z.P. Cellular trafficking of low molecular weight heparin incorporated in layered double hydroxide nanoparticles in rat vascular smooth muscle cells. Biomaterials 2011, 32:7234-7240.
40. Soltoff-Schiller B., Goldfischer S., Adamany A.M., Wolinsky H. Endocytosis by vascular smooth muscle cells in vivo and in vitro. Roles or vesicles and lysosomes. Am J Pathol 1976, 83:45-60.
41. Bennett M.R., Gibson D.F., Schwartz S.M., Tait J.F. Binding and phagocytosis of apoptotic vascular smooth muscle cells is mediated in part by exposure of phosphatidylserine. Circ Res 1995, 77:1136-1142.
42. Panyam J., Labhasetwar V. Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res 2003, 20:212-220.
43. Isayama N., Matsumura G., Yamazaki K. Comparison of vascular smooth muscle cells in canine great vessels. BMC Vet Res 2013, 9:1-8.
44. Arjona A.A., Hsu C.A., Wrenn D.S., Hill N.S. Effects of natriuretic peptides on vascular smooth-muscle cells derived from different vascular beds. Gen Pharmacol 1997, 28:387-392.
45. Zhang B., Liu Y., Luo Y., Niu W., Li Z.C. Alteration of serotonin 2C receptor expression in the aorta and the pulmonary artery in rats exposed to hypoxia. Chin J Physiol 2008, 51:338-347.
46. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
47. Stawowy P., Blaschke F., Kilimnik A., Goetze S., Kallisch H., Chretien M., et al. Proprotein convertase PC5 regulation by PDGF-BB involves PI3-kinase/p70(s6)-kinase activation in vascular smooth muscle cells. Hypertension 2002, 39:399-404.
48. Ogawa A., Firth A.L., Smith K.A., Maliakal M.V., Yuan J.X. PDGF enhances store-operated Ca2+ entry by upregulating STIM1/Orai1 via activation of Akt/mTOR in human pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol 2012, 302:C405-C411.
49. Krymskaya V.P., Snow J., Cesarone G., Khavin I., Goncharov D.A., Lim P.N., et al. mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. FASEB J 2011, 25:1922-1933.
50. Paddenberg R., Stieger P., von Lilien A.L., Faulhammer P., Goldenberg A., Tillmanns H.H., et al. Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice. Respir Res 2007, 8:15.
51. Kristof A.S., Pacheco-Rodriguez G., Schremmer B., Moss J. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms. J Pharmacol Exp Ther 2005, 314:1134-1143.
52. Tirado O.M., Mateo-Lozano S., Notario V. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax: Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity. Oncogene 2005, 24:3348-3357.
53. Ghobrial I.M., Witzig T.E., Adjei A.A. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005, 55:178-194.
54. Sorkin A., Von Zastrow M. Signal transduction and endocytosis: close encounters of many kinds. Nat Rev Mol Cell Biol 2002, 3:600-614.
55. Sahay G., Querbes W., Alabi C., Eltoukhy A., Sarkar S., Zurenko C., et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol 2013, 31:653-658.
56. Hunter A.C., Moghimi S.M. Cationic carriers of genetic material and cell death: a mitochondrial tale. Biochim Biophys Acta 2010, 1797:1203-1209.
57. Kongkaneramit L., Sarisuta N., Azad N., Lu Y., Iyer A.K., Wang L., et al. Dependence of reactive oxygen species and FLICE inhibitory protein on lipofectamine-induced apoptosis in human lung epithelial cells. J Pharmacol Exp Ther 2008, 325:969-977.
58. Makino K., Ohshima H., Kondo T. Transfer of protons from bulk solution to the surface of poly(L-lactide) microcapsules. J Microencapsul 1986, 3:195-202.
59. Stolnik S., Garnett M.C., Davies M.C., Illum L., Bousta M., Vert M., et al. The colloidal properties of surfactant-free biodegradable nanospheres from poly(β-malic acid-co-benzyl malate)s and poly(lactic acid-co-glycolide). Colloid Surf A Physicochem Eng Asp 1995, 97:235-245.